Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers

The transcription factor SOX9 plays a crucial role in normal prostate development and has been suggested to drive prostate carcinogenesis in concert with PTEN inactivation. To evaluate the clinical impact of SOX9 and its relationship with key genomic alterations in prostate cancer, SOX9 expression w...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-06, Vol.10 (6), p.e0128525
Main Authors: Burdelski, Christoph, Bujupi, Erzen, Tsourlakis, Maria Christina, Hube-Magg, Claudia, Kluth, Martina, Melling, Nathaniel, Lebok, Patrick, Minner, Sarah, Koop, Christina, Graefen, Markus, Heinzer, Hans, Wittmer, Corinna, Sauter, Guido, Wilczak, Waldemar, Simon, Ronald, Schlomm, Thorsten, Steurer, Stefan, Krech, Till
Format: Article
Language:English
Subjects:
Analysis
Antigens
Cancer
Cancer genetics
Carcinogenesis
Carcinogens
Deactivation
DNA microarrays
Ethics
Gene expression
Glands
Humans
Immunohistochemistry
Inactivation
Male
Medical prognosis
Medical research
Metastases
Middle Aged
Pathology
Patients
Prostate cancer
Prostate-Specific Antigen - blood
Prostatic Neoplasms - genetics
Prostatic Neoplasms - pathology
PTEN Phosphohydrolase - genetics
PTEN protein
Recurrence
Sox9 protein
SOX9 Transcription Factor - genetics
Stem cells
Surgery
Thoracic surgery
Trans-Activators - genetics
Transcription factors
Transcriptional Regulator ERG
Tumorigenesis
Tumors
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The transcription factor SOX9 plays a crucial role in normal prostate development and has been suggested to drive prostate carcinogenesis in concert with PTEN inactivation. To evaluate the clinical impact of SOX9 and its relationship with key genomic alterations in prostate cancer, SOX9 expression was analyzed by immunohistochemistry on a tissue microarray containing 11,152 prostate cancers. Data on ERG status and deletions of PTEN, 3p13, 5q21 and 6q15 were available from earlier studies. SOX9 expression levels were comparable in luminal cells of normal prostate glands (50% SOX9 positive) and 3,671 cancers lacking TMPRSS2:ERG fusion (55% SOX9 positive), but was markedly increased in 3,116 ERG-fusion positive cancers (81% SOX9 positive, p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0128525